Cambridge id 7286296

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Cambridge id 7286296
• 英文别名: 2,2,2-trichloro-N-[(3,4-dichlorophenyl)methyl]acetamide
• 化学式: C₉H₆Cl₅NO
• 分子量: 321.4
• InChiKey: UUAXTHSSTBYJHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• QUINOXALINE COMPOUND
  申请人：Kaizawa Hiroyuki

  公开号：US20110319385A1

  公开（公告）日：2011-12-29

  [Problem] Provided is a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like. [Means for Solution] The present inventors have investigated a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like, and thus, have found that an imidazoquinoxaline compound or a triazoloquinoxaline compound has a PDE9-inhibiting action, thereby completing the present invention. The imidazoquinoxaline compound or the triazoloquinoxaline compound of the present invention has a PDE9-inhibiting action and can be used as an agent for preventing and/or treating storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like.

  提供一种具有PDE9抑制作用的化合物，可用作治疗和/或预防储存功能障碍、排尿功能障碍、膀胱/尿道疾病等药剂的活性成分。现有发明人研究了一种具有PDE9抑制作用的化合物，可用作治疗和/或预防储存功能障碍、排尿功能障碍、膀胱/尿道疾病等药剂的活性成分，因此，发现咪唑喹喔啉化合物或三唑喹喔啉化合物具有PDE9抑制作用，从而完成了本发明。本发明的咪唑喹喔啉化合物或三唑喹喔啉化合物具有PDE9抑制作用，可用作预防和/或治疗储存功能障碍、排尿功能障碍、膀胱/尿道疾病等药剂。
• 6-Fluorobicyclo[3.1.0]hexane derivatives
  申请人：Nakazato Atsuro

  公开号：US20050119345A1

  公开（公告）日：2005-06-02

  An antidepressant comprising, as an active ingredient, a compound having an antagonistic effect on group II metabotropic glutamate receptors, as well as a 2-amino-3-alkoxy-6-fluoro-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative of Formula [I]: [wherein R 1 and R 2 , which may be the same or different, each represent a hydroxyl group, a C 1-10 alkoxy group, etc.; R 3 represents a C 1-10 acyl group, a C 1-6 alkoxy-C 1-6 acyl group, etc.; and R 4 and R 5 , which may be the same or different, each represent a hydrogen atom, a C 1-10 alkyl group, etc.] or a pharmaceutically acceptable salt or hydrate thereof.

  一种抗抑郁药，包含作为活性成分的一种具有对II类代谢型谷氨酸受体拮抗作用的化合物，以及公式[I]的2-氨基-3-烷氧基-6-氟-双环[3.1.0]己烷-2,6-二羧酸衍生物：[其中R1和R2，可以相同或不同，分别代表羟基，C1-10烷氧基等；R3代表C1-10酰基，C1-6烷氧基-C1-6酰基等；R4和R5，可以相同或不同，分别代表氢原子，C1-10烷基等]或其药学上可接受的盐或水合物。
• 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative
  申请人：Yasuhara Akito

  公开号：US20070021394A1

  公开（公告）日：2007-01-25

  A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administraiton A 2-amino-bicyclo[3.1.0] hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R 1 and R 2 are identical or different, and each represents a hydrogen atom, a C 1-10 alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR 3 R 4 or the like (wherein R 3 and R 4 are identical or different, and each represents a hydrogen atom, a C 1-10 alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.

  一种药物，可用于治疗和预防精神障碍，如精神分裂症、焦虑症及相关疾病、抑郁症、双相情感障碍和癫痫等。该药物拮抗II类代谢型谷氨酸受体的作用，并在口服给药中表现出高活性。该药物是2-氨基双环[3.1.0]己烷-2,6-二羧酸酯衍生物，化学式为[I]（其中R1和R2相同或不同，分别表示氢原子，C1-10烷基或类似物；X表示氢原子或氟原子；Y表示—OCHR3R4或类似物（其中R3和R4相同或不同，分别表示氢原子，C1-10烷基或类似物；n表示整数1或2），其药学上可接受的盐或水合物。
• 2-Amino-Bicyclo (3.1.0) Hexane-2,6-Dicarboxylic Ester Derivative
  申请人：YASUHARA Akito

  公开号：US20090306408A1

  公开（公告）日：2009-12-10

  A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R 1 and R 2 are identical or different, and each represents a hydrogen atom, a C 1-10 alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR 3 R 4 or the like (wherein R 3 and R 4 are identical or different, and each represents a hydrogen atom, a C 1-10 alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.

  一种药物，对治疗和预防精神障碍如精神分裂症、焦虑和相关疾病、抑郁症、躁郁症和癫痫有效。该药物拮抗II类代谢型谷氨酸受体的作用，在口服给药时显示出高活性。该药物为2-氨基-双环[3.1.0]己烷-2,6-二羧酸酯衍生物，化学式为[I]（其中R1和R2相同或不同，分别表示氢原子、C1-10烷基或类似物；X表示氢原子或氟原子；Y表示—OCHR3R4或类似物（其中R3和R4相同或不同，分别表示氢原子、C1-10烷基或类似物；n表示整数1或2），其药物可接受的盐或水合物。
• 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE
  申请人：YASUHARA Akito

  公开号：US20120004232A1

  公开（公告）日：2012-01-05

  A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.

  一种药物，有效治疗和预防精神障碍，如精神分裂症，焦虑和相关疾病，抑郁症，双相障碍和癫痫。该药物拮抗II类代谢型谷氨酸受体的作用，在口服给药中显示高活性。该药物是2-氨基-双环[3.1.0]己烷-2,6-二羧酸酯衍生物，由式[I]表示[其中R1和R2相同或不同，每个代表氢原子，C1-10烷基或类似物; X代表氢原子或氟原子; Y代表—OCHR3R4或类似物（其中R3和R4相同或不同，每个代表氢原子，C1-10烷基或类似物; n表示整数1或2）]，其药学上可接受的盐或水合物。